Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers - Jahn, Arne; Rump, A.; Widmann, T. J.; Heining, C.; Horak, Peter; Hutter, Barbara; Paramasivam, Nagarajan; Uhrig, Sebastian; Gieldon, Laura; Drukewitz, S.; Kübler, A.; Bermudez, M.; et al. (Annals of oncology, 2022)
Online veröffentlicht am 18. August 2022, Artikelversion 25. Oktober 2022